Type of Assessment:
A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts
Clinical and Experimental Medicine 2026 February 20 [Link] Elton Jalis Herman, Alessandra Allione, Clara Viberti, Marcello Manfredi 2, Alessia Russo, Khadija Sana-Hafeez, Nina Kaiser, Georg Johnen, Thomas Brüning, Dario Mirabelli, Irma Dianzani, Antonio Agudo, Elisabete Weiderpass, Vittorio Simeon, Rudolf Kaaks, Renée Turzanski-Fortner, Rosario Tumino, Lorenzo Milani, José María Gálvez-Navas, Matthias B Schulze, Catarina Schiborn, Natalia…
Read MorePresent and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review
European Respiratory Review 2026 February 18 [Link] Amro Hajja, Miral Atout, Rasoul Turko, Haadi Syed, Paula Duarte D’Ambrosio, Ricardo Mingarini Terra, Amal Abdulhaq, Marco Nardini, Marcello Carlo Ambrogi, Marco Lucchi, Hassan Robaidi, Waleed Saleh, Khaled AlKattan, Marcello Migliore Abstract Background: Pleural malignancies pose a significant clinical challenge due to their poor prognosis and limited treatment…
Read MoreAnalysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study
Frontiers in Oncology 2026 February 3 [Link] Zhi-Ran Yang, Xin-Li Liang, Xin-Bao Li, Xin-Jing Zhang, He-Liang Wu, Yan-Dong Su, Yan Li, Song-Lin An Abstract Objective: To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant…
Read MoreOptimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies
Thorax 2026 February 17 [Link] Christophe Blanquart, Arnaud Scherpereel Abstract Background: Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed/platinum-based chemotherapy has been challenged since 2020 by dual immunotherapy, that is, anti-programmed cell death-1 (anti-PD-1) + anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors and recently by combination of…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read MoreSATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma
Cells 2026 February 2 [Link] Cynthia Brown, Shivam Srivastava, Rohit Srivastava, Rashmi Srivastava, Jason Morvant, Anju Shrivastava, Rakesh K Srivastava Abstract SATB2 (special AT-rich binding protein 2) functions as a chromatin-associated epigenetic regulator that modulates gene expression, in part by serving as a transcriptional cofactor. This study assessed whether SATB2 overexpression is sufficient to promote…
Read MoreRadiofrequency Ablation for Recurrent Pleural Mesothelioma
Cancers 2026 January 26 [Link] Hiroshi Kodama, Kozo Kuribayashi, Haruyuki Takaki, Kosuke Matsuda, Takashi Shinkai, Reona Wada, Atsushi Ogasawara, Masaki Hashimoto, Daichi Fujimoto, Toshiyuki Minami, Soichiro Funaki, Takashi Kijima, Koichiro Yamakado Abstract Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read MoreBAP-1 in the diagnosis of malignant pleural mesothelioma
Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists. Patients and methods: This study included all patients diagnosed with pleural mesothelioma between October 2013…
Read MoreValidation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models
Scientific Reports 2026 February 11 [Link] Huaikai Shi, Sakthi Priya Selvamani, Richard Zelei, Ling Zhuang, Dongwei Wang, Ben Johnson, Vivek Dharwal, Duo Xu, Yiwei Wang, Tristan Rutland, Sonja Klebe, Steven Kao, Anthony Linton, Elham Hosseini-Beheshti, Yuen Yee Cheng Abstract Pleural mesothelioma (PM) is a highly aggressive cancer with limited treatment efficacy and poor prognosis. Conventional…
Read More
Skip to content